Wanhai Medical aspires to become the world's largest supplier of injection pens by shipment volume by 2031.
Wanhai Medical is a leading developer and manufacturer of self medical injection system solutions in China.
Founded in 2016, specializes in the R&D,manufacturing, and sales of various pen injectors. Wanhai Medical has been awarded the national titles of"National High-Tech Enterprise" and "Specialized, Sophisticated,and Innovative Enterprise".
The company currently has a plant area of 12,000-square-meters,and a new 36,000-square-meters under construction. There are more than 300 employees, including over 50 senior R&D engineers, graduates of leading science and technology universities, 20+ specialists in the regulatory affairs, 20+ specialists in the quality assurance, and 20+professionals in the Sales & Marketing. Now, Wanhai Medical has the ability to consistently produce 90 million disposable and reusable pen injectors annually. Upon completion of our new facility, Wanhai Medical will establish an automated, intelligent production base with a total annual capacity of 400 million units.
Recombinant Human Insulin, Insulin Aspart, Insulin Glargine, Insulin Degludec, Insulin Lispro, etc
Widely used in the monoclonal antibody drugs that packed by prefilled syringe for the treatment of anti-tumor, chronic disease, autoimmune diseases.
Glucagon-Like Peptide-1 (GLP-1), i.e. Liraglutide, Exenatide, Dulaglutide, Semaglutide, etc.
Growth Hormone (GH), Follicle-Stimulating Hormone (FSH) Parathyroid Hormone (PTH) , Etc.
